Dianthus Therapeutics (DNTH) to Release Earnings on Thursday

Key Points

• Dianthus Therapeutics (NASDAQ: DNTH) is set to announce its Q2 2025 earnings on August 14th, with analysts predicting a loss of ($0.86) per share.
• The company's recent Q1 earnings report showed a loss of ($0.82) per share, exceeding expectations with revenue of $1.16 million against an estimate of $0.81 million.
• Stock for Dianthus Therapeutics is currently down 4.0%, with a recent market cap of $655.74 million and a consensus target price of $53.00 from analysts.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.86) per share and revenue of $0.87 million for the quarter.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.87 million. Dianthus Therapeutics had a negative return on equity of 33.78% and a negative net margin of 2,364.56%. On average, analysts expect Dianthus Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH traded down $0.39 during midday trading on Friday, reaching $18.76. 307,019 shares of the stock were exchanged, compared to its average volume of 332,393. The business has a 50-day simple moving average of $19.29 and a two-hundred day simple moving average of $20.04. The company has a market capitalization of $603.32 million, a price-to-earnings ratio of -5.77 and a beta of 1.43. Dianthus Therapeutics has a 12 month low of $13.36 and a 12 month high of $32.27.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on DNTH. Robert W. Baird reduced their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Finally, William Blair assumed coverage on shares of Dianthus Therapeutics in a research report on Wednesday, July 2nd. They set an "outperform" rating on the stock. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $53.00.

Institutional Investors Weigh In On Dianthus Therapeutics

An institutional investor recently raised its position in Dianthus Therapeutics stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 4.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,334 shares of the company's stock after acquiring an additional 618 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Dianthus Therapeutics were worth $280,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.